NCT07708610Not yet recruiting
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes: A Target Trial Emulation
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare preadmission glucose-lowering treatment strategies in adults with type 2 diabetes hospitalized with pneumonia. Time zero is the date of the index pneumonia admission. The study compares patients with evidence of prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission with patients prescribed a GLP-1 receptor agonist alone, an SGLT2 inhibitor alone, or usual care. Usual care includes metformin, sulfonylureas, or DPP-4 inhibitors without either study class. The primary outcome is a composite of all-cause death, invasive mechanical ventilation, or renal replacement therapy within 30 days of admission, with the individual components and 12-month mortality, major adverse cardiovascular events, and major adverse kidney events also evaluated. Propensity-score methods are used to reduce bias from nonrandom treatment selection.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 71775 (estimated)
- First submitted
- 13 Jul 2026
- Start date
- 31 Jul 2026
- Primary completion date
- 31 Aug 2026
- Lead sponsor
- Chung Shan Medical University
- Diseases
- Type 2 diabetes
- NCT number
- NCT07708610
What you commit to
- Study type: Observational
- Planned participants: 71775
- From 31 Jul 2026 to the primary completion date, 31 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Bariatric surgery
- Solid-organ transplantation
- Pneumonia hospitalization, invasive mechanical ventilation, or renal replacement therapy in the year before the index admission
- Acute cardiovascular event in the 6 months before the index admission
Other illness
- Type 1 diabetes mellitus, or other specified diabetes types that are not type 2 diabetes
- Human immunodeficiency virus infection
- End-stage kidney disease, dialysis dependence, ventilator dependence, or tracheostomy status
- Metastatic malignancy, lung cancer, or palliative care
- Viral pneumonia, influenza with pneumonia, or COVID-19 around the index admission
Who the study is looking for
- Adults aged 18 years or older.
- Type 2 diabetes mellitus
- Hospitalization with pneumonia during the study period, serving as the index admission
- Prescription of a GLP-1 receptor agonist, an SGLT2 inhibitor, or usual-care glucose-lowering therapy in the year before the index admission
- No GLP-1 receptor agonist or SGLT2 inhibitor prescription in the 6 months before the first qualifying prescription
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chung Shan Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.